AboutHTA Guidelines for the Economic Evaluation of Health Technologies

of 75
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
  Canadian Agency for Drugs and Technologiesin Health Agence canadienne des médicaments et des technologies de la santé Supporting Informed Decisions hta Guidelines for the Economic Evaluation of Health Technologies: Canada 3rd Edition, 2006   * An amendment was made after  the initial publication in March 2006.  Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Cite as:   Guidelines for the economic evaluation of health technologies: Canada  [3 rd  Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. This report and the French version entitled  Les lignes directrices de l’évaluation économique des produits  pharmaceutiques au Canada  are available on CADTH’s web site. Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories,  Nova Scotia, Nunavut, Ontario, Prince Edward Island, Québec, Saskatchewan, and Yukon. The Canadian Agency for Drugs and Technologies in Health takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CADTH. CADTH is funded by Canadian federal, provincial and territorial governments. Legal Deposit - 2006  National Library of Canada ISBN: 1-897257-08-2 (print) ISBN: 1-897257-09-0 (online) PUBLICATIONS MAIL AGREEMENT NO. 40026386 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH 600-865 CARLING AVENUE OTTAWA ON K1S 5S8    In memory of Bernie O’Brien, BA, MSc, PhD   (1959-2004)   The Canadian Agency for Drugs and Technologies in Health dedicates this work to the memory of Bernie O’Brien, an outstanding health economist, researcher, and educator, but above all, our highly valued and respected colleague. Internationally renowned as a pioneer in economic evaluation as it relates to health care, Dr. O’Brien was the Director of PATH (Program for Assessment of Technology in Health), Professor in the Department of Clinical Epidemiology and Biostatistics, and an Associate of the Centre for Health Economics and Policy Analysis at McMaster University; Associate Director of the Centre for Evaluation of Medicines at St. Joseph’s Healthcare, and Director of the Clinical Effectiveness Research of the Father Sean O’Sullivan Research Centre, Hamilton, Ontario. His wisdom, foresight, and enthusiasm are sorely missed.     GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: CANADA Canadian Agency for Drugs and Technologies in Health i This report is a review of existing public literature, studies, materials and other information and documentation (collectively the “source documentation”) which are available to CADTH. The accuracy of the contents of the source documentation on which this report is based is not warranted, assured or represented in any way by CADTH and CADTH does not assume responsibility  for the quality, propriety, inaccuracies or reasonableness of any statements, information or conclusions contained in the source documentation. CADTH takes sole responsibility for the final form and content of this report. The statements and conclusions in this report are those of CADTH and not of its Panel members or reviewers. CADTH Scientific Advisory Panel Reviewers André-Pierre Contandriopolous, PhD Full Professor Health Administration Université de Montréal Montréal QC Douglas Coyle, MA MSc PhD Associate Professor, Department of Epidemiology and Community Health University of Ottawa Ottawa ON David Hailey, MSc PhD GradRIC Professor, Public Health Sciences University of Alberta Edmonton AB Philip Jacobs, DPhil Professor University of Alberta Edmonton AB Muhammad Mamdani, MA MPH PharmD (At the time of document review) Senior Scientist Institute for Clinical Evaluative Sciences Toronto ON CADTH Advisory Committee on Pharmaceuticals Reviewers The following individuals reviewed early drafts of the third edition. Roy Dobson, BSc Pharm MBA PhD Assistant Professor University of Saskatchewan Saskatoon SK RS Nakagawa, BSc FCSHP (At the time of document review) Director Pharmacy Fraser Health Authority Surrey BC John A. Hoar, BA MPA MDE Pharmaceutical Economist  Nova Scotia Department of Health Halifax NS Angie Wong, BScPhm MSc Acting Associate Director, Pharmaceutical Services Drug Programs Branch Ontario Ministry of Health and Long-Term Care Toronto ON CADTH Devices and Systems Advisory Committee Paul Childs, BA (Hon) Manager, Business Planning Business Intelligence Program Alberta Health and Wellness Edmonton AB
Similar documents
View more...
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks